These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38006237)

  • 41. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.
    Fanaroff AC; Kaltenbach LA; Peterson ED; Akhter MW; Effron MB; Henry TD; Wang TY
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center.
    Dalal JJ; Digrajkar A; Gandhi A
    Indian Heart J; 2016; 68(5):624-631. PubMed ID: 27773400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
    Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome.
    Lattuca B; Mazeau C; Cayla G; Ducrocq G; Guedeney P; Laredo M; Dumaine R; El Kasty M; Kala P; Nejjari M; Hlinomaz O; Morel O; Varenne O; Leclercq F; Payot L; Spaulding C; Beygui F; Rangé G; Motovska Z; Portal JJ; Vicaut E; Collet JP; Montalescot G; Silvain J;
    JACC Cardiovasc Interv; 2024 Feb; 17(3):359-370. PubMed ID: 38355265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Zhang Z; Chen O
    J Cardiovasc Pharmacol; 2021 May; 77(5):536-543. PubMed ID: 33760801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
    Husted S; James SK; Bach RG; Becker RC; Budaj A; Heras M; Himmelmann A; Horrow J; Katus HA; Lassila R; Morais J; Nicolau JC; Steg PG; Storey RF; Wojdyla D; Wallentin L;
    Eur Heart J; 2014 Jun; 35(23):1541-50. PubMed ID: 24682844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention.
    Li J; Qiu H; Yan L; Guo T; Wang Y; Li Y; Zheng J; Tang Y; Xu B; Qiao S; Yang Y; Gao R
    Curr Med Res Opin; 2020 Nov; 36(11):1739-1745. PubMed ID: 32945695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention.
    Zhang D; Li P; Qiu M; Liang Z; He J; Li Y; Han Y
    Atherosclerosis; 2024 Mar; 390():117395. PubMed ID: 38114408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
    Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
    EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Gill K; Servati N; Flahive J; Fraielli K
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
    Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.
    Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW
    Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
    Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
    Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Dehghani P; Lavoie A; Lavi S; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN
    Am Heart J; 2017 Oct; 192():105-112. PubMed ID: 28938956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized Comparison of Intensified and Standard P2Y
    Mehilli J; Baquet M; Hochholzer W; Mayer K; Tesche C; Aradi D; Xu Y; Thienel M; Gschwendtner S; Zadrozny M; Jochheim D; Sibbing D; Schüpke S; Mansmann U; Hoffmann E; Kastrati A; Neumann FJ; Massberg S
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008649. PubMed ID: 32527192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.